L-selectin expression is low on CD34+ cells from patients with chronic myeloid leukemia and interferon-a up-regulates this expression

• Published in: Haematologica (Roma) Vol. 85; no. 2; pp. 139 - 146
• Main Authors: Martin-Henao, GA, Quiroga, R, Sureda, A, Gonzalez, , JR, Moreno, V, Garcia, J
• Format: Journal Article
• Language: English
• Published: Italy 01.02.2000
• Subjects: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Cell Adhesion Molecules - biosynthesis; Female; Flow Cytometry; Hematopoietic Stem Cells - drug effects; Hematopoietic Stem Cells - metabolism; Humans; Interferon-alpha - pharmacology; Interferon-alpha - therapeutic use; L-Selectin - biosynthesis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology; Male; Middle Aged; Tumor Cells, Cultured
• ISSN: 0390-6078; 1592-8721

Department of Cryobiology and Cell Therapy, Cancer Research Institute, Hospital Duran i Reynals, Av. Castelldefels, Km 2.7, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. gmartinh@iro.es. BACKGROUND AND OBJECTIVE: Altered adhesive interaction between bone marrow (BM) stroma and progenitors in chronic myeloid leukemia (CML) may be in part caused by abnormal expression of cell adhesion molecules (CAMs) on malignant progenitor cells. Treatment of CML with interferon-a (IFN-a) re-establishes normal hemopoiesis in some patients in part by restoring normal adhesive interactions between CML progenitors and BM microenvironment, which may in turn be mediated by correcting CAM expression on progenitors. DESIGN AND METHODS: We investigated the expression of CAMs (L-selectin, b((2))-integrin, LFA-3, ICAM-1, ICAM-3, NCAM) on purified BM CD34(+) cells from CML patients (n= 34) and healthy adults (n= 15) by flow cytometry. Modulation of L-selectin expression on CD34(+) cells from CML after in vitro treatment with IFN-a was also investigated. RESULTS: The mean percentage of CD34(+ )cells expressing L-selectin was significantly lower in CML patients (25.4+/-12.8%) than in normal controls (68.7+/-8.3%, n=15). CD34(+)/HLA-DR( /low) and CD34(+)/ CD38( /low) co-expressing L-selectin were also significantly lower in untreated CML (27.4+/-21.5% and 39.8+/-26.7%, respectively, n=8) than in controls (61+/-17% and 83.7+/-10%, respectively, n=7). In vitro treatment with IFN-a of purified CD34(+) BM cells from untreated CML patients (n=8) induced a significant, dose and time-dependent increase in the L-selectin expression as indicated by FACS analysis. INTERPRETATION AND CONCLUSIONS: We hypothesize that this L-selectin deficiency reflects a cell surface adhesion defect of progenitors from CML that is partially restored by in vitro IFN-a treatment. These data may help to explain the adhesive abnormalities of CML progenitors to the BM microenvironment and the in vitro restoration of adhesion capacity after IFN-a treatment.